Taladegib
- Generic Name
- Taladegib
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24F4N6O
- CAS Number
- 1258861-20-9
- Unique Ingredient Identifier
- QY8BWX1LJ5
- Background
Taladegib has been used in trials studying the treatment of Solid Tumor, COLON CANCER, BREAST CANCER, Advanced Cancer, and Rhabdomyosarcoma, among others.
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
- Conditions
- Idiopathic Pulmonary FibrosisProgressive Fibrosing Interstitial Lung Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Endeavor Biomedicines, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT06422884
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Endeavor Biomedicines, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT05817240
- Locations
- 🇦🇺
Research Site, Adelaide, South Australia, Australia
A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Endeavor Biomedicines, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04968574
- Locations
- 🇲🇽
Research Site, Puebla, Mexico
🇰🇷Research Site (Bundang District), Seongnam, Korea, Republic of
🇰🇷Research Site (Namdong District), Incheon, Korea, Republic of
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
- Conditions
- Soft Tissue SarcomaColon CancerSolid TumorBreast CancerCholangiocarcinoma
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 94
- Registration Number
- NCT02784795
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
- Conditions
- Stage II Esophageal Adenocarcinoma AJCC v7Stage IIA Esophageal Adenocarcinoma AJCC v7Stage IIB Esophageal Adenocarcinoma AJCC v7Stage IIIB Esophageal Adenocarcinoma AJCC v7Stage IB Esophageal Adenocarcinoma AJCC v7Stage IIIA Esophageal Adenocarcinoma AJCC v7Gastroesophageal Junction Adenocarcinoma
- Interventions
- Radiation: External Beam Radiation TherapyOther: Laboratory Biomarker Analysis
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT02530437
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of LY2940680 in Japanese Participants With Advanced Cancers
- First Posted Date
- 2013-08-09
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 19
- Registration Number
- NCT01919398
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-858-255-5959 Mon - Fri from 9 AM to 5 PM Pacific Time (PST), or speak with your personal physician., Tokyo, Japan
A Study of LY2940680 in Small Cell Lung Cancer
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2018-12-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 26
- Registration Number
- NCT01722292
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇺🇸Northwest Cancer Specialists PC, Vancouver, Washington, United States
🇬🇧For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom
A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2013-08-27
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT01697514
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States
A Study in Advanced Cancer
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 84
- Registration Number
- NCT01226485
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tyler, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.